Anti-CD24 Antibody (SWA11) 

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

CD24

Anti-CD24 Antibody (SWA11) (10 μg/mL; 15-90 min), cnjugated with Alexa-488, is rapidly internalised by SKOV3ip human ovarian carcinoma cells, with a 200% increase in intracellular fluorescence intensity observed after 90 min of incubation^[1].
Anti-CD24 Antibody (SWA11) decreases the proliferation of human pancreatic, ovarian, and lung cancer cells in vitro^[2].
Anti-CD24 Antibody (SWA11) pretreatment enhances the anti-tumor efficacy of gemcitabine, 5-fluorouracil, oxaliplatin, doxorubicin, paclitaxel, and irinotecan in general human tumor cells, and enhances the anti-tumor efficacy of cisplatin in human embryonal carcinoma cells in vitro^[2].
SWA11-DOX, a conjugate of Anti-CD24 Antibody (SWA11) and doxorubicin, is rapidly internalized into small-cell lung cancer cells, inhibits thymidine incorporation by 50%, and is 100 times more selective than free doxorubicin^[2].
Anti-CD24 Antibody (SWA11) binds to CD24 on CD24-positive tumor cells to trigger internalization, modify STAT3-dependent gene expression and Src phosphorylation, directly reduce tumor cell proliferation, adhesion, and invasion, while also activating ADCC and complement to enhance anti-tumor efficacy^[2].
Anti-CD24 Antibody (SWA11) (1 μg/mL) specifically detects CD24 protein in HT-29 human CRC cell lysates, with no detection in CD24-negative HCT116 human CRC cell lysates^[3].
Anti-CD24 Antibody (SWA11) (1.6-16 μg/mL; 1 h) selectively binds to CD24-positive HT-29 human CRC cells, with no significant binding to CD24-negative HCT116 human CRC cells^[3].
Anti-CD24 Antibody (SWA11) (10 μg/mL; 30 min) binds specifically to CD24-positive human CRC cells, as measured by flow cytometry^[3].
Anti-CD24 Antibody (SWA11) (24 h) does not inhibit protein synthesis in HT-29 or HCT116 human CRC cell lines^[3].
Anti-CD24 Antibody (SWA11) (48 h) does not induce apoptosis in HT-29 human CRC cells following 48 hours of treatment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-CD24 Antibody (SWA11) (10 mg/kg; 4 times with 5-day interval) reduces A549 lung carcinoma xenograft growth relative to controls, decreases tumor cell proliferation and blood vessel density, and significantly alters the intratumoral cytokine milieu in female SCID beige mice^[1].
Anti-CD24 Antibody (SWA11) (10 mg/kg; twice weekly; 4 weeks) reduces SKOV3ip ovarian carcinoma xenograft endpoint weight by relative to controls, decreases tumor cell proliferation and blood vessel density, and increases macrophage infiltration in female athymic CD1 nu/nu mice^[1].
Anti-CD24 Antibody (SWA11) (10 mg/kg; once per treatment cycle, 3 total cycles, 1 day prior to gemcitabine) potentiates the anti-tumor efficacy of gemcitabine, reducing A549 lung carcinoma xenograft growth in female SCID beige mice^[1].
Anti-CD24 Antibody (SWA11) slows tumor growth in human colorectal cancer xenografts, modulates the tumor immune microenvironment, and enhances the anti-tumor efficacy of several chemotherapy agents^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

100133941  [NCBI]

P25063-1

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.67 kDa

Liquid

Colorless to light yellow

[Anti-CD24 Antibody (SWA11)]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow cytometric analysis of 1×10⁶ MCF-7 cells with Anti-CD24 Antibody (SWA11) (HY-P991196, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Salnikov AV, et al. Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas. Br J Cancer. 2013;108(7):1449-1459.  [Content Brief]

  [2]. Huang S, et al. Checkpoint CD24 function on tumor and immunotherapy. Front Immunol. 2024;15:1367959. Published 2024 Feb 29.  [Content Brief]

  [3]. Shapira S, et al. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology. 2011;140(3):935-946.  [Content Brief]